Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways
Harn, Donald A.
MetadataShow full item record
CitationBhargava, Prerna, Changlin Li, Kristopher J. Stanya, David Jacobi, Lingling Dai, Sihao Liu, Matthew R. Gangl, Donald A. Harn, and Chih-Hao Lee. 2012. Immunomodulatory glycan lnfpiii alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways. Nature medicine 18(11): 1665-1672.
AbstractParasitic worms express host-like glycans to attenuate the immune response of human hosts. The therapeutic potential of this immunomodulatory mechanism in controlling metabolic dysfunction associated with chronic inflammation remains unexplored. We demonstrate here that administration of Lacto-N-fucopentaose III (LNFPIII), a LewisX containing immunomodulatory glycan found in human milk and on parasitic helminths, improves glucose tolerance and insulin sensitivity in diet-induced obese mice. This effect is mediated partly through increased Il-10 production by LNFPIII activated macrophages and dendritic cells, which reduces white adipose tissue inflammation and sensitizes the insulin response of adipocytes. Concurrently, LNFPIII treatment up-regulates nuclear receptor Fxr-α (or Nr1h4) to suppress lipogenesis in the liver, conferring protection against hepatosteatosis. At the signaling level, the extracellular signal-regulated kinase (Erk)-Ap1 pathway appears to mediate the effects of LNFPIII on both inflammatory and metabolic pathways. Our results suggest that LNFPIII may provide novel therapeutic approaches to treat metabolic diseases.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11375889
- SPH Scholarly Articles